Sanofi expanded the sales reach of the drug with approvals in the lucrative chronic obstructive pulmonary disease (COPD) ...

Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand ...

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and ...

Developed using Regeneron's VelocImmune technology, Dupixent is a fully human monoclonal antibody that blocks the interleukin-4 (IL4) and interleukin-13 (IL13) signalling pathways.

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

Regeneron-partnered Dupixent, the crown jewel of Sanofi’s commercial portfolio, continued to impress with 21.1% sales growth ...

Discover how a new, less invasive procedure is revolutionizing the diagnosis and treatment of pediatric digestive issues, offering hope to families.

Dupixent included in list of overseas approved drugs that meet urgent clinical need in China. Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the National Medical Products ...